PR
Prothena Corporation plc
PRTA · NASDAQ
$8.38 -4.66% (-$0.41)
1M -12.80%
Market Cap $438.7M
P/E Ratio -
Div. Yield -
ROE 14.98%
Analiza
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Piotroski F-Score Weak
3/9Valuation
52 /100
Fair P/S 8.05x
P/B 1.53x
P/E N/A
Growth
0 /100
Declining Rev. growth 43.57%
Book val. growth 23.32%
EPS growth N/A
Profitability
17 /100
Weak Gross margin 43.52%
FCF margin 111.34%
Net margin 80.67%
Quality
2 /100
Poor ROIC 21.54%
Asset turnover 0.18x
ROE 14.98%
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 25.05x
Int. coverage N/A
Stability
20 /100
Unstable Beta -0.33x
Profitable years 0
Rev. volatility 88.16%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o PRTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gene G. Kinney
Employees
67
Headquarters
Dublin
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report